Share Facebook
Crohn's Disease Forum » Books, Multimedia, Research & News » Hospira launches first biosimilar monoclonal antibody (mAb) Inflectra™ (infliximab) in major European markets


02-16-2015, 06:32 AM   #1
DustyKat
Super Moderator
 
DustyKat's Avatar
 
Join Date: May 2010
Location: New South Wales, Australia
Hospira launches first biosimilar monoclonal antibody (mAb) Inflectra™ (infliximab) in major European markets

-- Major European markets can finally benefit from the availability of Inflectra following the patent expiry of reference product Remicade® (infliximab)
-- Inflectra provides an alternative, potentially more affordable treatment option for people suffering from severe, debilitating diseases such as rheumatoid arthritis and inflammatory bowel disease while maintaining comparable quality, efficacy and safety to the reference product
-- As a result of competition, the large savings expected to be generated with biosimilars can provide an opportunity to improve patient access to life-changing medications.
Full Article:

http://finance.yahoo.com/news/hospir...095500870.html
__________________
Mum of 2 kids with Crohn's.
02-16-2015, 09:39 AM   #2
nogutsnoglory
Moderator
 
nogutsnoglory's Avatar
 
Join Date: Sep 2009
Location: New York

My Support Groups:
Fantastic! Hopefully more who need this will be able to access this without financial Barrier.
02-16-2015, 11:03 AM   #3
FrozenGirl
Senior Member
 
FrozenGirl's Avatar
 
Join Date: Jan 2014

My Support Groups:
An interesting note: in Canada Inflectra was approved for most indications of Remicade but not Crohns or UC. Health Canada basically said there was a small difference that could affect the way it works in CD and UC.
__________________
Dx: Ulcerative Colitis, Nov 2013
Currently on:
Mezavant 4.8g
Vitamin D 1000iu
Calcium
Tecta 40mg
Remicade: 600mg, every 4 weeks
Methotrexate: 15 mg (injection)
06-24-2015, 06:43 AM   #4
droopymonthly
 
Join Date: Mar 2015
Location: Adelaide, South Australia, Australia
An interesting note: in Canada Inflectra was approved for most indications of Remicade but not Crohns or UC. Health Canada basically said there was a small difference that could affect the way it works in CD and UC.
Could you please be more specific? Does it mean the cheaper alternative does not work for CD?
BTW, what is the current price for Inflctra in Canada?
__________________
Diagnosis: confirmed CD in 03/2015 by flexible sigmoidoscopy at age 34. But it started from 2006 and misdiagnosised by all doctors before.
Surgeries: 2 times fistulotomies(2007, 2009), endoscopic dilation of pylorus(2011) , 2 times abscess drainages(03/2015, 06/2015)
Meds for CD: AZA 100mg + Remicade
Currently in: No symptom and everything is under control.
06-24-2015, 08:16 AM   #5
kiny
Senior Member
 
kiny's Avatar
 
Join Date: Apr 2011
Could you please be more specific? Does it mean the cheaper alternative does not work for CD?
It doesn't mean that at all. But biosimilars are different from generics, because of how they are manufactured, biosimilars are far more complex . A different cell line during manufacturing can completely change the effectiveness of a medication, this isn't the case with generics.

Part of this argument is justified, biosimilars will need more testing than a generic. Generics are for all intended purposes, the same thing, biosimilars, not completely. Part of it is also just manufacturers trying to prevent cheaper biosimilars to enter the market.
06-26-2015, 10:11 PM   #6
FrozenGirl
Senior Member
 
FrozenGirl's Avatar
 
Join Date: Jan 2014

My Support Groups:
"The indications for psoriatic arthritis and plaque psoriasis were granted on the basis of similarity and the absence of meaningful differences, between Inflectra and the reference product, in product quality, mechanism of action, disease pathophysiology, safety profile, dosage regimen and on clinical experience with the reference product. Scientific rationales submitted by the sponsor were found to be adequate to support extrapolation to the indications and uses pertaining to psoriatic arthritis and plaque psoriasis; however, extrapolation to indications and uses pertaining to Crohn's disease and ulcerative colitis could not be recommended due to differences between Inflectra and the reference product, that could have an impact on the clinical safety and efficacy of these products in these indications. As a result, the benefit/risk assessments for Inflectra in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis were considered to be positive, while the benefit/risk assessment of Inflectra in patients with Crohn's disease or ulcerative colitis could not be completed. Additional information is presented in the Clinical Efficacy and Characterization of the Drug Substance sections."

From: http://www.hc-sc.gc.ca/dhp-mps/prodp...159493-eng.php
06-26-2015, 10:17 PM   #7
FrozenGirl
Senior Member
 
FrozenGirl's Avatar
 
Join Date: Jan 2014

My Support Groups:
At the submitted price ($650.00 per 100 mg vial), Inflectra is less costly than Remicade ($987.56 per 100 mg vial) for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic plaques, and psoriatic arthritis.
From http://www.pdci.ca/2015/01/05/cdec-f...lectra-posted/

Not official on the health Canada website but sounds right.
04-06-2016, 12:18 PM   #8
xeridea
Senior Member
 
xeridea's Avatar
 
Join Date: Jul 2014

My Support Groups:
Yesterday, the FDA approved Inflectra (infliximab biosimilar) for all conditions for which Remicade is already approved.

On a related topic, a Samsung subsidiary is also moving forward with their infliximab biosimilar. Flixabi recently received favorable review by the European advisory committee so it moves a step closer to approval there.

Last edited by xeridea; 04-06-2016 at 02:21 PM.
Reply

Crohn's Disease Forum » Books, Multimedia, Research & News » Hospira launches first biosimilar monoclonal antibody (mAb) Inflectra™ (infliximab) in major European markets
Thread Tools


All times are GMT -5. The time now is 10:27 AM.
Copyright 2006-2017 Crohnsforum.com